(where en is ethylenediamine and acac is acetylacetonate); the crystal structure of 3 is described. The central hypothesis of our work is that combining a bioactive compound such as KTZ and a metal in a single molecule results in a synergy that can translate into improved activity and/or selectivity against parasites. In agreement with this hypothesis, complexation of KTZ with Ru II in compounds 3-5 produces a marked enhancement of the activity toward promastigotes and intracellular amastigotes of Leishmania major, when compared with uncomplexed KTZ, or with similar ruthenium compounds not containing KTZ. Importantly, the selective toxicity of compounds 3-5 toward the leishmania parasites, in relation to human fibroblasts and osteoblasts or murine macrophages, is also superior to the selective toxicities of the individual constituents of the drug. When tested against Trypanosoma cruzi epimastigotes, some of the organometallic complexes displayed activity and selectivity comparable to those of free KTZ. A dual-target mechanism is suggested to account for the antiparasitic properties of these complexes.
Introduction
Leishmaniasis is one of the world's most neglected diseases, affecting mainly the poorest populations of developing countries. This disease, caused by more than 20 species and subspecies of a hemoflagellate protozoan of the genus Leishmania, is endemic in 88 countries; some two million new cases occur yearly, and 350 million people are considered at risk of contracting leishmaniasis [1, 2] . American trypanosomiasis (Chagas disease), caused by Trypanosoma cruzi [3] , is also largely neglected by public health programs, the media, and pharmaceutical companies; it affects over 20 million people in Central America and South America, of which up to five million develop severe digestive and cardiac impairments, causing 10,500-15,000 deaths per year and a heavy burden of people unable to work [4] [5] [6] [7] .
Leishmaniasis has been traditionally treated with pentavalent antimonial compounds such as pentostam and glucantime, or with amphotericin B in unresponsive cases, whereas chemotherapy for Chagas disease typically uses benznidazole or nifurtimox. These treatments suffer, in most of cases, from toxicity problems, limited efficacy, and emerging resistance; thus, the search for novel chemotherapeutic agents for these ailments clearly requires urgent attention. Over the last several years we have demonstrated the efficacy of metal-drug synergy [8, 9] in searching for new therapies against T. cruzi and Leishmania major; the approach involves combining a compound of known antiparasitic activity and a metal in a single molecule. The resulting metal-based drugs display enhanced activity and reduced toxicity toward mammalian cells when compared with their individual constituents. These favorable features are the result of improved physicochemical properties and novel mechanisms of action involving dual or multiple targets [8, 9] . Our strategy makes use of the fact that sterol 14-demethylases have been validated as chemotherapeutic targets for trypanosomatids; in particular, azole and triazole compounds cause a depletion of normal sterols and an accumulation of abnormal amounts of sterol precursors with cytostatic or cytotoxic consequences [10] [11] [12] [13] [14] [15] [16] . We have demonstrated that attaching such azole-type sterol biosynthesis inhibitors (SBIs), specifically clotrimazole (CTZ) or ketoconazole (KTZ), to metal-containing fragments (Ru, Rh, Ir, Au, and Cu) effectively enhances their activity against T. cruzi, while maintaining a low toxicity for mammalian cells [17] [18] [19] [20] .
Other researchers have described a number of metal derivatives with interesting anti-Chagas-disease and antileishmanial activity targeting different biochemical pathways; they include complexes of palladium, platinum, and ruthenium with nitrofuran thiosemicarbazones, pentamidine, pyridine-2-thiol-N-oxide, dithiocarbazates, or aryl-4-oxothiazolylhydrazones [21] [22] [23] [24] [25] . Rhodium-, iridium-, platinum-, and copper-containing moieties coordinated to pentamidine, or to the DNA intercalator dipyrido[3,2-a:2 0 ,3 0 -c]phenazine [8, 9, [26] [27] [28] , and cyclometallated gold, palladium, and rhenium derivatives with cathepsin B inhibitory ability [29] have also shown interesting activity.
Recently we reported a remarkable series of organometallic compounds containing Ru II and CTZ which display unprecedentedly high in vitro antiparasitic activity combined with very low toxicity toward normal mammalian cells [30] . In particular, [Ru II (g 6 -p-cymene)Cl 2 (CTZ)] shows an enhancement of the activity of CTZ by a factor of 110 against L. major promastigotes and by a factor of 58 against T. cruzi epimastigotes, resulting in low nanomolar and low micromolar lethal doses, respectively. In addition, [Ru II (g 6 -p-cymene)Cl 2 (CTZ)] does not exhibit any appreciable toxicity toward human osteoblasts when assayed up to 7.5 lM, which translates into excellent selectivity indexes higher than 500 for L. major and 75 for T. cruzi. This compound also significantly inhibited the proliferation of intracellular amastigotes of L. major in infected intraperitoneal mouse macrophages (70 % inhibitory concentration 29 nM). In vivo testing and detailed mechanistic studies of these ruthenium-CTZ complexes are currently in progress.
In 4 ] (6) (where en is ethylenediamine and acac is acetylacetonate). In vitro assays reveal a marked enhancement of the activity against L. major promastigotes and amastigotes for complexes 3-5 when compared with KTZ or with similar ruthenium compounds not containing KTZ, together with a low toxicity toward mammalian cells. When tested against T. cruzi epimastigotes, some of the organometallic complexes displayed activity and selectivity comparable to those of KTZ. (20 mL) , and AgBF 4 (0.39 g, 1.98 mmol) was added. Precipitation of AgCl was observed while the solution turned brown. After removal of AgCl by filtration, KTZ (0.97 g, 1.83 mmol) was added and the mixture was stirred at room temperature for 2 h. The resulting brown suspension was filtered, and the filtrate was evaporated to dryness. The product was extracted with dichloromethane (25 mL), concentrated to approximately 2 mL, and precipitated by addition of hexane (20 mL 4 (0.13 g 0.64 mmol) was added. The color changed from dark brownish red to light orange and the appearance of AgCl was observed. The suspension was stirred at room temperature for 3 h and then filtered; the resulting orange solution was cooled to -20°C for 72 h to complete the precipitation of AgCl. After filtration, bipy (0.05 g, 0.32 mmol) was added and the mixture was stirred at room temperature for 3 h. The brown solution was concentrated to approximately 2 mL, and hexane (20 mL) was added to produce a dark-brown oil. The hexane layer was decanted and the addition and decantation of successive hexane portions (20 mL) yielded a brownish-orange solid, which was dried under a vacuum and redissolved in dichloromethane. KTZ (0.17 g, 0.32 mmol) was added and the solution was stirred at room temperature for 1 h, then concentrated to a volume of approximately 2 mL. Addition of hexane (20 mL) yielded the product as a light-brown precipitate, which was washed with hexane and diethyl ether, and finally dried under a vacuum. Yield 0.302 g, 87 %. 1 (20 mL) , and AgBF 4 (0.13 g 0.26 mmol) was added. The resulting suspension was stirred at room temperature for 2 h. The solvent was removed under a vacuum, and the residue was extracted with dichloromethane and filtered. To the resulting yellow solution, KTZ (0.14 g 0.26 mmol) was added, and the mixture stirred at room temperature for 12 h. The resulting greenish-yellow solution was filtered and concentrated under a vacuum to a volume of approximately 2 mL. The product was precipitated by addition of hexane (20 mL) to yield a fine yellow powder, which was washed with hexane and diethyl ether, and dried under a vacuum. Yield 0.148 g, 60 %. X-ray structure determination of complex 3 X-ray diffraction data were collected with a Bruker APEX II diffractometer. Crystal data, data collection parameters, and refinement parameters are summarized in Table 1 . A CIF file has been deposited with the Cambridge Crystallographic Data Centre (CCDC). CCDC 926335 contains the supplementary crystallographic data for this article. These data can be obtained free of charge from the CCDC via http://www. ccdc.cam.ac.uk/data_request/cif. The structure was solved using direct methods and standard difference map techniques, and refined by full-matrix least-squares procedures on F 2 with SHELXTL (version 6.10) [36, 37] .
Materials and methods

Materials
Biological activity
Trypanosomatid cultures
Epimastigote forms of T. cruzi Y strain (TcLuc-RAM) were grown in liver infusion tryptose medium [38] . Promastigote forms of L. major strain Friedlin clone V1 (Lm-luc) were grown in RPMI 1640 medium supplemented with hemin and 10 % fetal bovine serum inactivated at 56°C for 30 min [39] .
Culture of mammalian cells
U2OS human osteoblast (ATCCÒ HTB-96), Hs27 human fibroblast (ATCCÒ CRL-1634 TM ), and RAW 264.7 mouse macrophage (ATCC TIB-71) cells (American Type Culture Collection, Manassas, VA, USA) were cultured in Dulbecco's modified Eagle's medium supplemented with 10 % inactivated fetal bovine serum, along with 1 % 10,000 U/mL penicillin and 10 mg/mL streptomycin, in 0.9 % sodium chloride. Cell cultures were regularly tested for Mycoplasma by polymerase chain reaction [40] . Intraperitoneal mouse macrophages were obtained as previously described [41] and cultured in high-glucose Dulbecco's modified Eagle's medium supplemented with 10 % fetal bovine serum (inactivated). The procedure was performed in such as way as to minimize the distress and pain for animals following the NIH guidance and animal protocol approved by the Institutional Animal Care and Use Committee of the University of Texas at El Paso.
Evaluation of the toxicity toward mammalian cell lines
AlamarBlue assay The toxicity toward human osteoblasts and fibroblasts and murine macrophages was determined using alamarBlue, as previously described [42] . Intraperitoneal macrophages were tested at drug concentrations of 0.0586, 0.117, 0.234, 0.468, 0.937, 1.87, and 3.75 lM; RAW 264.7 macrophages were tested at drug concentrations of 0.117, 0.234, 0.468, 0.937, 1.87, 3.75, and 7.5 lM. Hs27 (human fibroblasts) and U2OS (human osteoblasts) were assayed at drug concentrations of 0.117, 0.234, 0.468, 0.937, 1.87, 3.75, 7.5, 15, 30, 60, and 120 lM.
Luciferase assay: L. major and T. cruzi The antiparasitic activity of complexes 1-6 was determined using the L. major strain Friedlin clone V1 (Lm-luc) and T. cruzi Y strain (TcLuc-RAM). The drugs (stock solutions in DMSO) were tested in a concentration range from 0.0586 to 30 lM; 1 lL was added per well (1 % DMSO final concentration) to 96-well microplates using an Eppendorf epMotion 5070 automated pipetting system. L. major promastigotes and T. cruzi epimastigotes (10 6 per well) were added, and parasite survival was assessed by luciferase activity with the substrate 5 0 -fluoroluciferin (ONE-Glo luciferase assay system, Promega) after 96 h incubation at 28°C, using a luminometer (Luminoskan, Thermo). The bioluminescence intensity was a direct measure of the survival of parasites. The assay was performed in triplicate in three independent experiments, from which the median lethal doses (LD 50 ) were determined for each drug.
In vitro evaluation of compounds 3-5 by high-content imaging assay: infectivity experiments To mimic in vivo infections, intraperitoneal mouse macrophages were placed in a microplate and infected with the metacyclic promastigote form of L. major strain Friedlin clone V1, followed by treatment with complexes 3-5. The macrophages were seeded at a density of 1 9 10 6 in a 96-well flat-bottomed microplate for 8 h prior to infection. The metacyclic promastigotes of L. major were collected and washed twice with phosphate-buffered saline at pH 7.2 (1,600g for 10 min) and their concentration was adjusted to 8 9 10 6 parasites per milliliter. The infection of macrophage cells was performed for 24 h, at a ratio of eight parasites per macrophage, in triplicate. After 24 h, the cells were washed twice with phosphate-buffered saline, and the infected cells were incubated with the drug. Several concentrations (0.058-3.75 lM) and incubation times were assayed. The cells were fixed with 4 % paraformaldehyde and stained with Alexa Fluor 488 phalloidin and 4 0 ,6-diamidino-2-phenylindole. The number of infected cells and amastigotes was determined by a high-content imaging assay using a BD Pathway Bioimager microplate confocal microscope [30, 43] . Subsequently, the infection index was calculated from the mean of triplicate values by multiplying the percentage of infected cells by the constraint used in the high-content imaging assay, which was five parasites per macrophage. The infection index is thus directly proportional to the percentage of infected cells. The statistical significance was determined.
Results and discussion
Synthesis and characterization of complexes 1-6 2 (bipy)], followed by addition of an equimolar amount of KTZ and refluxing overnight in chloroform (Scheme 1). After appropriate workup, the complexes are isolated in high yields as air-stable, lightyellow and light-brown solids, respectively. The NMR data ( 1 H, 13 C, correlation spectroscopy, nuclear Overhauser effect spectroscopy, and heteronuclear single quantum coherence) are consistent with coordination of KTZ through the N1 atom of the imidazole moiety (for assignments of all 1 H and 13 C NMR signals, see ''Materials and methods''; atom numbering in Fig. 1 ). For instance, the signals corresponding to H 2 and H 5 of coordinated KTZ in complex 1 are significantly shifted to higher frequencies (Dd = 1.00 and 0.75 ppm) with respect to uncomplexed KTZ. The 2D nuclear Overhauser effect spectroscopy spectrum reveals short distances between H 2 and H 5 and two of the three coordinated DMSO molecules in accord with the cis,fac stereochemistry expected by analogy with known related compounds [44] .
The ligand arrangement is further confirmed by the nuclear Overhauser effect interactions observed between all methyl groups of the DMSO molecules (Fig. 2) [45] have established that the formation of the alternative cis,mer isomer is not to be expected, e.g., for analogous ruthenium benzimidazole complexes, from the known reactivity of cis-[Ru II Cl 2 (DMSO) 4 ]. Compound 2 also shows chemical shifts for the imidazole protons that agree with nitrogen coordination to ruthenium. Interligand Overhauser effect analysis of 2 (Fig. 2) indicates a configuration where the bipy ligand adopts a trans disposition with respect to both chlorine atoms, and a cis configuration with respect to the KTZ and DMSO ligands. This is further confirmed by the observed nuclear Overhauser effect interactions of the ortho protons of bipy with both imidazole protons (H 2 and H 5 ) and with the methyl groups of DMSO.
The organometallic p-arene-ruthenium-KTZ derivatives, in turn, were synthesized from appropriate wellknown starting materials, as summarized in Scheme 2. 1 H and 13 C NMR spectroscopy and microanalysis; the complete assignment of all 1 H and 13 C NMR signals for the four complexes is presented in ''Materials and methods.'' Additionally, the crystal and molecular structure of compound 3 was determined by X-ray diffraction (vide infra).
X-ray structure of complex 3
Crystals of complex 3 were obtained by slow evaporation of a dichloromethane solution. Table 1 lists the crystal and refinement data; the molecular structure is shown in Fig. 3 and the most relevant bond lengths and angles are given in Table 2 . The coordination around the ruthenium center is essentially a ''piano-stool'' distorted octahedral arrangement that includes the p-cymene ring, two chlorides, and the N1 atom of the imidazole moiety of KTZ. The average Ru-C and Ru-Cl distances of 2.17 and 2.42 Å , respectively, as well as the Ru-N bond length of 2.115 (4) Å and the corresponding angles are within the normal range for similar molecules [46] , and specifically for Ru
Scheme 1 i ketoconazole (KTZ), CH 2 Cl 2 , room temperature. ii 2,2 0 -bipyridine (bipy), tetrahydrofuran, reflux. iii KTZ, CHCl 3 , reflux. DMSO dimethyl sulfoxide (BTZ is the bromo analogue of CTZ) [18] , and for the analogous CTZ compound [Ru II (g 6 -p-cymene)Cl 2 (CTZ)] recently reported by us [30] . Other structural features of the KTZ ligand are unremarkably analogous to those of the free molecule [47] .
Biological activity
The activity of the new ruthenium-KTZ complexes 1-6 against the proliferation of in vitro cultures of promastigotes of L. major and epimastigotes of T. cruzi was tested at various concentrations, in comparison with uncomplexed . Cytotoxicity assays were also performed on human fibroblasts and osteoblasts, as well as murine macrophages and intraperitoneal macrophages, in order to ascertain the selectivity of the compounds for attacking the parasites of interest over normal mammalian cells. The results of all bioassays are collected in Table 3 and Fig. 4 . Uncomplexed KTZ displays good in vitro activity and selectivity against promastigotes of L. major (LD 50 1.9 lM; selectivity index above 63). The ruthenium complexes not containing KTZ (C1-C3) are in turn much less active than KTZ against leishmania (LD 50 12-15 lM). However, by combining KTZ and ruthenium in single molecules, as in compounds 3-5, one can achieve the desired metal-drug synergy. The activity of the ruthenium-KTZ complexes (LD 50 0.8-1.5 lM) is about twice that of KTZ alone and at least ten times that of the structurally analogous ruthenium complex C3 not containing KTZ (LD 50 12.5 lM). Importantly, the enhancement of the antileishmanial activity of KTZ by ruthenium is accompanied by a significant increase in selectivity with respect to human cells (selectivity index 78-150).
To further assess the medicinal potential of the new ruthenium-KTZ complexes 3-5, additional tests were performed with the therapeutically more relevant infectious intracellular amastigote form of L. major, by means of a high-content imaging assay on infected intraperitoneal mouse macrophages (see ''Materials and Methods'').
As shown in Fig. 5a , complexes 3-5 showed significant inhibition of the proliferation of intracellular amastigotes, as compared with the negative control (culture medium with 1 % DMSO), within the range of concentrations used (0.11-3.75 lM). For complex 3, inhibition reached about 50 % at a concentration of 0.1 lM. In contrast, 5 lM concentration of the standard drug amphotericin B was needed to reach 30 % inhibition. Also importantly, no significant cytotoxicity for intraperitoneal mouse macrophages was observed for compounds 3-5 within the same concentration range (Fig. 5b) .
For T. cruzi epimastigotes, KTZ alone displays significant activity and selectivity, similar to those observed in the case of L. major (Table 3 ). The ruthenium complexes C1-C3, which do not feature a KTZ ligand, and complex 6, containing an acac ligand, are essentially nontoxic to the parasites. Complex 3 displays the best performance of this series, with activity and selectivity (LD 50 1.39 lM; selectivity index above 86) comparable to those observed for KTZ (LD 50 1.5 lM; selectivity index above 82); the efficacy decreases for complexes 4 and 5.
[Ru II (g 6 -p-cymene)Cl 2 (KTZ)] (3), the most active complex reported herein against both types of parasites, is structurally analogous to [Ru II (g 6 -p-cymene)Cl 2 (CTZ)], the most effective member of the arene-ruthenium-CTZ family reported by us before [30] . In an early article concerning the related compound RuCl 2 (CTZ) 2 . The hydrolysis is likely followed by interactions of the aqua species with biomolecules in the cellular medium that lead to dissociation of CTZ. Once liberated from the metal, CTZ exerts its known SBI action. The remaining ruthenium-containing moiety binds covalently to the DNA of the parasite as a second target, and the dual action leads to high activity and low toxicity [18] . We believe that an analogous mechanism involving initial activation by aquation is operative for [Ru II (g 6 -p-cymene)Cl 2 (CTZ)] [30] and for the present case of complex 3. In agreement with this hypothesis, electrical conductance measurements for 3 (10 -3 M in 10 % aqueous DMSO) reveal a value typical of two ions in solution (K = 115 lS cm -1 immediately after dissolution, increasing slowly to 130 lS cm The UV-visible spectrum of solutions of complex 3 (see the electronic supplementary material) also remains unchanged over a period of 72 h, consistent with the rapid formation of the cationic aqua species 3a. Additionally, diagnostic NMR signals around 7.8 ppm, assigned to H 2 of coordinated KTZ in complex 3, are present in the spectrum over a period of 72 h, whereas the spectral features typical of free KTZ are not observed; no broadening of the spectra due to the presence of paramagnetic Ru III species was detected over the same period of time. The combined conductivity and spectral data show that in aqueous DMSO medium at neutral pH (1) the chlorides are labile, (2) KTZ does not dissociate to any appreciable extent, and (3) no oxidation to paramagnetic Ru III occurs. Hydrolysis of one chloride ligand to form the cationic aqua species 3a appears to be a prerequisite for biological activity, and dissociation of KTZ probably occurs but only on further interactions of 3a with biomolecules within the parasite cell. [ (5) are less active than 3 against L. major and T. cruzi; the lower performance observed may be a consequence of the presence of chelating en or bipy ligands, which are not susceptible to easy exchange with water. The antiparasitic activity observed could be related to a combination of the SBI action of dissociated KTZ and the ability of nitrogen-chelating ligands on the remaining ruthenium-containing fragment to promote interactions with DNA through hydrogen bonding in the case of en [48, 49] , or by p-stacking interactions for bipy [50, 51] . Complex 6, on the other hand, does not contain any ligands that can be easily hydrolyzed or that promote DNA interactions, and in consequence, it is the least effective of the organometallic species against L. major and is essentially nontoxic to T. cruzi. The octahedral coordination complexes 1 and 2 are less active against L. major or T. cruzi than the organometallic derivatives 3-6, also in agreement with the trend previously reported by us for analogous CTZ derivatives [30] . Further mechanistic studies on the chemical and biological pathways that lead to the antiparasitic action of these rutheniumbased drugs are currently in progress in our laboratories.
Conclusion
In an effort to discover new metal-based agents against leishmaniasis and Chagas disease, six new ruthenium-KTZ complexes were synthesized and characterized, namely, cis,fac-[Ru II Cl 2 (DMSO) 3 (6); the crystal structure of 3 was determined by X-ray diffraction methods. In agreement with the metal-drug synergy that we have previously proposed, binding of KTZ to Ru II in compounds 3-5 led to a marked increase of the activity against promastigotes and intracellular amastigotes of L. major when compared with uncomplexed KTZ or with similar ruthenium compounds not containing KTZ. Importantly, the selectivity of compounds 3-5 toward leishmania parasites, in relation to normal human cells, is also higher than the selectivities observed for the individual constituents of the drug. When tested against T. cruzi epimastigotes, some of the organometallic complexes displayed activity and selectivity comparable to those of free KTZ. A dual-target mechanism is suggested to account for the antiparasitic properties of these complexes by analogy with a previous proposal for the related complex RuCl 2 (KTZ) 2 . Conductivity and spectroscopic data for complex 3 show that in aqueous media at neutral pH (1) the chlorides are labile, (2) KTZ does not dissociate to any appreciable extent, and (3) no oxidation to paramagnetic Ru III occurs. Hydrolysis of the chloride ligands to form cationic aqua species appears to be a prerequisite for biological activity, and dissociation of KTZ probably occurs but only on further interactions of the active species with biomolecules within the parasite cell.
